潜在莽草酸激酶抑制剂对结核分枝杆菌的毒理学分析

IF 3 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Atla-Alternatives To Laboratory Animals Pub Date : 2024-01-01 Epub Date: 2023-12-14 DOI:10.1177/02611929231217062
Ashish Jhangiani, Vandana Panda, Aanchal Sukheja, Sneha Thomas, Piyush Dusseja, Siddhartha Pandya, Anand Chintakrindi
{"title":"潜在莽草酸激酶抑制剂对结核分枝杆菌的毒理学分析","authors":"Ashish Jhangiani, Vandana Panda, Aanchal Sukheja, Sneha Thomas, Piyush Dusseja, Siddhartha Pandya, Anand Chintakrindi","doi":"10.1177/02611929231217062","DOIUrl":null,"url":null,"abstract":"<p><p>Over the last decade, <i>Mycobacterium tuberculosis</i> has mutated into a putative 'superbug', as treatments against it have failed due to increasing antimicrobial resistance. As a result, the rising incidence of multidrug-resistant tuberculosis (MDR-TB) is posing a significant public health threat, thus, the need to develop effective drugs for MDR-TB has become an urgent priority. To identify new drug candidates for the treatment of MDR-TB, the present study was based on mycobacterial shikimate kinase (MtSK) as the pharmacological target. One hundred potential MtSK inhibitors were identified from literature and database searches to identify compounds that were designed to specifically function as MtSK antagonists. The ADME properties of these compounds were evaluated by using the SwissADME web tool. ProTox-II software was also used to investigate any potential endocrine disrupting effects, mediated through their interaction with oestrogenic and/or androgenic receptors. This study also aimed to predict LD<sub>50</sub> values of potential drug candidates that would be active against the standard H37Rv strain of <i>M. tuberculosis</i>, by using the ProTox-II <i>in silico</i> tool. The molecules for which no structural hazard alerts were identified with these software tools were further subjected to molecular docking analyses and molecular dynamic simulations to estimate their ability to interact with the MtSK enzyme. Preliminary results from SwissADME indicated that 30 molecules were drug-like, due to their physicochemical and pharmacokinetic properties. However, subsequent analysis with ToxTree and ProTox-II indicated that only three of these 30 drug-like molecules were suitable for taking forward into further <i>in vitro</i> experiments. This study, which is based on the use of commonly used open-source <i>in silico</i> tools, identified new MtSK ligands for potential use in the development of new drugs for the therapeutic management of tuberculosis. An initial prediction of their safety profile was also generated.</p>","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":" ","pages":"10-27"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Toxicological Profiling of Potential Shikimate Kinase Inhibitors Against <i>Mycobacterium tuberculosis</i>.\",\"authors\":\"Ashish Jhangiani, Vandana Panda, Aanchal Sukheja, Sneha Thomas, Piyush Dusseja, Siddhartha Pandya, Anand Chintakrindi\",\"doi\":\"10.1177/02611929231217062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Over the last decade, <i>Mycobacterium tuberculosis</i> has mutated into a putative 'superbug', as treatments against it have failed due to increasing antimicrobial resistance. As a result, the rising incidence of multidrug-resistant tuberculosis (MDR-TB) is posing a significant public health threat, thus, the need to develop effective drugs for MDR-TB has become an urgent priority. To identify new drug candidates for the treatment of MDR-TB, the present study was based on mycobacterial shikimate kinase (MtSK) as the pharmacological target. One hundred potential MtSK inhibitors were identified from literature and database searches to identify compounds that were designed to specifically function as MtSK antagonists. The ADME properties of these compounds were evaluated by using the SwissADME web tool. ProTox-II software was also used to investigate any potential endocrine disrupting effects, mediated through their interaction with oestrogenic and/or androgenic receptors. This study also aimed to predict LD<sub>50</sub> values of potential drug candidates that would be active against the standard H37Rv strain of <i>M. tuberculosis</i>, by using the ProTox-II <i>in silico</i> tool. The molecules for which no structural hazard alerts were identified with these software tools were further subjected to molecular docking analyses and molecular dynamic simulations to estimate their ability to interact with the MtSK enzyme. Preliminary results from SwissADME indicated that 30 molecules were drug-like, due to their physicochemical and pharmacokinetic properties. However, subsequent analysis with ToxTree and ProTox-II indicated that only three of these 30 drug-like molecules were suitable for taking forward into further <i>in vitro</i> experiments. This study, which is based on the use of commonly used open-source <i>in silico</i> tools, identified new MtSK ligands for potential use in the development of new drugs for the therapeutic management of tuberculosis. An initial prediction of their safety profile was also generated.</p>\",\"PeriodicalId\":55577,\"journal\":{\"name\":\"Atla-Alternatives To Laboratory Animals\",\"volume\":\" \",\"pages\":\"10-27\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Atla-Alternatives To Laboratory Animals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/02611929231217062\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/12/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atla-Alternatives To Laboratory Animals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02611929231217062","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

在过去的十年中,结核分枝杆菌已变异为一种假定的 "超级细菌",由于抗菌药耐药性的增加,对它的治疗已经失败。因此,耐多药结核病(MDR-TB)的发病率不断上升,对公共卫生构成了严重威胁,因此,开发治疗耐多药结核病的有效药物已成为当务之急。为了确定治疗 MDR-TB 的候选新药,本研究以分枝杆菌莽草酸激酶(MtSK)为药理靶点。通过文献和数据库搜索,确定了 100 种潜在的 MtSK 抑制剂,从而找出了专门设计为 MtSK 拮抗剂的化合物。使用 SwissADME 网络工具对这些化合物的 ADME 特性进行了评估。此外,还使用 ProTox-II 软件调查了这些化合物通过与雌激素和/或雄激素受体相互作用而可能产生的内分泌干扰效应。这项研究还旨在通过使用 ProTox-II 硅工具,预测对标准 H37Rv 结核杆菌株具有活性的潜在候选药物的半数致死剂量。对使用这些软件工具未发现结构危险警报的分子进一步进行了分子对接分析和分子动力学模拟,以估计其与 MtSK 酶相互作用的能力。SwissADME 的初步结果表明,有 30 种分子因其理化和药代动力学特性而类似于药物。然而,随后使用 ToxTree 和 ProTox-II 进行的分析表明,这 30 个类药物分子中只有 3 个适合进一步进行体外实验。这项研究基于常用的开放源代码硅学工具,发现了新的 MtSK 配体,可用于开发治疗结核病的新药。此外,还对这些配体的安全性进行了初步预测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Toxicological Profiling of Potential Shikimate Kinase Inhibitors Against Mycobacterium tuberculosis.

Over the last decade, Mycobacterium tuberculosis has mutated into a putative 'superbug', as treatments against it have failed due to increasing antimicrobial resistance. As a result, the rising incidence of multidrug-resistant tuberculosis (MDR-TB) is posing a significant public health threat, thus, the need to develop effective drugs for MDR-TB has become an urgent priority. To identify new drug candidates for the treatment of MDR-TB, the present study was based on mycobacterial shikimate kinase (MtSK) as the pharmacological target. One hundred potential MtSK inhibitors were identified from literature and database searches to identify compounds that were designed to specifically function as MtSK antagonists. The ADME properties of these compounds were evaluated by using the SwissADME web tool. ProTox-II software was also used to investigate any potential endocrine disrupting effects, mediated through their interaction with oestrogenic and/or androgenic receptors. This study also aimed to predict LD50 values of potential drug candidates that would be active against the standard H37Rv strain of M. tuberculosis, by using the ProTox-II in silico tool. The molecules for which no structural hazard alerts were identified with these software tools were further subjected to molecular docking analyses and molecular dynamic simulations to estimate their ability to interact with the MtSK enzyme. Preliminary results from SwissADME indicated that 30 molecules were drug-like, due to their physicochemical and pharmacokinetic properties. However, subsequent analysis with ToxTree and ProTox-II indicated that only three of these 30 drug-like molecules were suitable for taking forward into further in vitro experiments. This study, which is based on the use of commonly used open-source in silico tools, identified new MtSK ligands for potential use in the development of new drugs for the therapeutic management of tuberculosis. An initial prediction of their safety profile was also generated.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.80
自引率
3.70%
发文量
60
审稿时长
>18 weeks
期刊介绍: Alternatives to Laboratory Animals (ATLA) is a peer-reviewed journal, intended to cover all aspects of the development, validation, implementation and use of alternatives to laboratory animals in biomedical research and toxicity testing. In addition to the replacement of animals, it also covers work that aims to reduce the number of animals used and refine the in vivo experiments that are still carried out.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信